Att%25252525252525252525252520drugs

# Att drugs (Attention-Deficit/Hyperactivity Disorder Medications) ## Overview ADHD medications are primarily classified as stimulants (methylphenidate or amphetamine derivatives) or non-stimulants (atomoxetine, alpha-2 agonists, or viloxazine). They work by modulating norepinephrine and dopamine levels in the prefrontal cortex. ## Primary Indications * Attention-Deficit/Hyperactivity Disorder (ADHD) * Narcolepsy (specifically stimulants) * Binge-Eating Disorder (lisdexamfetamine only) ## Adult Dosing * **Methylphenidate (e.g., Concerta, Ritalin LA):** Initial 18–20 mg QD; titrate weekly. Max 72–108 mg/day depending on formulation. * **Lisdexamfetamine (Vyvanse):** Initial 30 mg QD. Max 70 mg/day. * **Mixed Amphetamine Salts (Adderall XR):** Initial 20 mg QD. Max 60 mg/day. * **Atomoxetine:** Initial 40 mg/day; increase to target 80 mg/day after 3 days. Max 100 mg/day. ## Pediatric Dosing * **Methylphenidate (Ages 6+):** Initial 5 mg BID or 18 mg extended-release QD. Titrate by 5–10 mg毎週. Max 60 mg/day. * **Lisdexamfetamine (Ages 6+):** Initial 30 mg QD. Max 70 mg/day. * **Atomoxetine (Ages 6+):** 0.5 mg/kg/day; increase after 3 days to target 1.2 mg/kg/day. Max 80–100 mg (based on weight). * *Note: Dosing must be based on current weight-based protocols; follow local pediatric formulary guidelines.* ## Dose Adjustments * **Renal/Hepatic:** Atomoxetine requires 50% dose reduction in patients with moderate hepatic impairment (Child-Pugh B) and 75% in severe impairment (Child-Pugh C). Stimulants generally do not require specific renal adjustments but use caution in severe impairment. ## Contraindications * Known hypersensitivity to sympathomimetic amines. * Advanced arteriosclerosis, symptomatic cardiovascular disease, or moderate-to-severe hypertension. * Hyperthyroidism or glaucoma. * Concomitant use with MAOIs (within 14 days). * Atomoxetine: Phaeochromocytoma. ## Adverse Effects * **Common:** Decreased appetite, insomnia, dry mouth, headache, tachycardia, and irritability (the "crash"). * **Serious:** Cardiovascular events (arrhythmias, sudden death in high-risk patients), priapism, peripheral vasculopathy (Raynaud’s), and suicidality (notably atomoxetine). ## Key Drug Interactions * **MAOIs:** Risk of hypertensive crisis; do not combine. * **Serotonergic agents:** Risk of serotonin syndrome when combined with atomoxetine or high-dose stimulants. * **Antacids/PPIs:** May alter absorption of certain extended-release stimulants. * **CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine):** Increase plasma concentrations of atomoxetine. ## Monitoring * **Baseline:** Cardiac history, blood pressure (BP), and heart rate (HR). * **Ongoing:** BP and HR at every dose titration and at least every 6 months during maintenance. Monitor height/weight in children. Assess for new onset of psychiatric symptoms (anxiety, aggression, suicidal ideation). ## Clinical Pearls * Extended-release (ER/XR) formulations are preferred over immediate-release (IR) to improve adherence and reduce abuse potential. * "Drug holidays" (e.g., discontinuing on weekends) may be considered to mitigate growth suppression or tolerance but should be evaluated on an individual basis. * Atomoxetine may take 2–4 weeks for initial clinical response and 6–8 weeks for full efficacy. * Lisdexamfetamine is a prodrug requiring enzymatic cleavage, potentially reducing abuse potential and systemic variability. *** **Educational Disclaimer:** This information is for educational purposes only. ADHD medication dosing and safety regulations vary by region and patient-specific factors. Always verify current prescribing information, contraindications, and local institutional protocols via official drug references (e.g., UpToDate, Lexicomp, or PI package inserts) before making clinical decisions.